



# Plasma substance P and soluble P-selectin as biomarkers of $\beta$ -thalassemia induced hypercoagulability



Samia A. Ebeid <sup>a</sup>, Nadia A. Sadek <sup>b</sup>, Sanaa A. El-Benhawy <sup>c,\*</sup>, Gihan N. Mahmoud <sup>b</sup>

<sup>a</sup> Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Egypt

<sup>b</sup> Hematology Department, Medical Research Institute, Alexandria University, Egypt

<sup>c</sup> Radiation Sciences Department, Medical Research Institute, Alexandria University, Egypt

Received 12 March 2013; accepted 21 August 2013

Available online 19 September 2013

## KEYWORDS

Thalassemia;  
Hypercoagulability;  
Tachykinins;  
P-selectin

**Abstract** *Background:* Hypercoagulability in thalassemia especially in thalassemia major has emerged as a complication of the disease. There is evidence of increased platelet aggregation and increased proportion of platelets expressing P-selectin in thalassemia. P-selectin is a cell adhesion molecule which plays a key role in hemostasis and thrombosis, mediating platelet rolling and generating procoagulant molecules. Substance P is one of the tachykinins which constitute a family of neuropeptides. It now appears that platelets contain substance P which is released upon stimulation leading to faster and more extensive aggregation.

*Objective:* To detect the possible role of substance P and soluble P-selectin (sP-selectin) as biomarkers of hypercoagulability in patients with beta-thalassemia major.

*Subjects and methods:* Venous blood samples were collected from ten normal control subjects and thirty patients with beta-thalassemia major (divided into two groups, splenectomized and unsplenectomized). To all studied individuals, plasma substance P and sP-selectin were assayed by an enzyme linked Immunosorbent assay (ELISA).

\* Corresponding author.

E-mail addresses: [nadsadek@yahoo.com](mailto:nadsadek@yahoo.com) (N.A. Sadek), [dr\\_sanaa\\_ali13@yahoo.com](mailto:dr_sanaa_ali13@yahoo.com) (S.A. El-Benhawy).

<sup>1</sup> Present/permanent address: Radiation Sciences Department, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, El-Hadra 21561, Egypt.

Peer review under responsibility of Alexandria University Faculty of Medicine.



Production and hosting by Elsevier

**Results:** Higher levels of plasma substance P and sP-selectin were observed in thalassemic patients versus the controls. Both substance P and sP-selectin were significantly higher in the splenectomized group of patients.

**Conclusions:** Substance P and sP-selectin might have a role in platelet activation and subsequent hypercoagulability in thalassemic patients.

© 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.

## 1. Introduction

beta-thalassemia is an inherited autosomal recessive hematologic disorder that causes hemolytic anemia because of the decreased or absent synthesis of the beta-globin chain.<sup>1</sup> In Egypt, it was estimated that 1000/1.5 million per year live births will suffer from thalassemia. beta-thalassemia is the most common type with a carrier rate ranging from 5.3% to  $\geq 9\%$  and a gene frequency of 0.03%.<sup>2</sup>

beta-thalassemia is clinically classified into: thalassemia major, intermedia and minor depending on the demand for blood transfusion and pathophysiology. The mainstay of managing these patients relies on blood transfusion and chelation. A state of hypercoagulability has been recognized in beta-thalassemia but the mechanisms underlying it are still unsettled.<sup>3</sup>

Platelet activation has been incriminated in starting the hypercoagulable state. Enhanced thrombin generation activates the platelets, monocytes, granulocytes and endothelial cells which further enhance the prothrombotic process.<sup>4</sup> There is evidence of increased platelet aggregation and increased proportion of platelets expressing P-selectin in thalassemia. P-selectin (CD62P) is a member of the selectin family of cell adhesion receptors, which mediate binding to specific carbohydrate ligands.<sup>5</sup> P-selectin is stored in  $\alpha$ -granules of platelets and Weibel–Palade bodies of endothelial cells.<sup>6</sup> Upon cellular activation, P-selectin translocates with the granule to the cell surface, where it mediates adhesion to leukocytes or endothelium.<sup>7</sup>

Substance P is a member of the tachykinin family of peptides and has clinically been considered a neuropeptide. Its interaction with tachykinin receptors on vascular endothelial or smooth muscle cells can cause vasodilation or contraction, respectively.<sup>8</sup> It now appears that platelets contain substance P which is released upon stimulation leading to faster and more extensive aggregation.<sup>9</sup>

The aim of the present work was to investigate the role of plasma substance P and soluble P-selectin (sP-selectin) as biomarkers of beta-thalassemia induced hypercoagulability.

## 2. Subjects and methods

Thirty patients with beta-thalassemia major followed up at the Hematology Department, Medical Research Institute were enrolled. A written consent for participating in the study was taken according to the declaration of Helsinki and approved by the ethics committee of the Medical Research Institute. Because splenectomy is a well known risk factor for thrombosis in thalassemia patients,<sup>10</sup> they were divided into two groups:

### 2.1. Group I

Fifteen unsplenectomized patients, their mean age was (22.37  $\pm$  8.96) years.

### 2.2. Group II

Fifteen splenectomized patients, their mean age was (20.28  $\pm$  7.53) years.

Ten age and sex matched healthy individuals served as normal control group. Venous blood sample was withdrawn from control subjects and from patients after an overnight fasting and just prior to blood transfusion. To all studied individuals, a full history taking and clinical examination were done. Laboratory investigations included: complete blood picture,<sup>11</sup> serum ferritin and liver and kidney function tests. The plasma levels of circulating substance P and sP-selectin were assayed by ELISA (R&D Systems, USA).

All patients received blood transfusion at a rate of one unit packed red blood cells every fortnight. They were chelated by desferrioxamine and the oral chelator deferipone. Most of them were infected with hepatitis C virus.

### 2.3. Statistical analyses

Statistical analyses were conducted using the statistical software package of SPSS version 11.5 (SPSS Inc, Chicago, USA). Differences between groups were assessed by the Mann Whitney *U* test for nonparametric variables. Pearson's correlation coefficients were calculated to evaluate the association between relevant parameters. Statistical significance was set at  $p < 0.05$ .

## 3. Results

As can be seen in (Table 1), there was no statistically significant difference in white blood cell count (WBC) among the studied groups and controls ( $P = 0.97$  and  $P = 0.46$  respectively). No statistically significant difference was found in hemoglobin concentration on comparing both groups. A significantly higher normoblast count (/100WBC) was found in the splenectomized group compared to the unsplenectomized group ( $P = 0.001$ ). The mean platelet volume (MPV) did not differ among the studied groups. The median value of platelet count in the splenectomized group was significantly higher than that in control and unsplenectomized groups ( $P = 0.001$  and  $P = 0.000$  respectively). Furthermore, splenectomized group had a higher serum ferritin level compared to the unsplenectomized group ( $P = 0.021$ ). Also it was higher in patient groups versus the controls ( $P = 0.000$ ).

**Table 1** Hematological results in all studied groups.

		Control group ( <i>n</i> = 10)	Patients with $\beta$ thalassemia major	
			Unsplenectomized group ( <i>n</i> = 15)	Splenectomized group ( <i>n</i> = 15)
WBC ( $\times 10^9/L$ )	Range	5–8	4.2–10	3.3–46.8
	Median	6.5	6.0	7.6
	P		0.97	0.46
Hb (g/dl)	Range	11.6–14.9	6.4–10.5	7.1–10.9
	Median	12.65	8.75	8.2
	P		0.000*	0.000*
Normoblast count/100 WBC	Range	0–0	0–80	0–460
	Median	0	20	31
	P		0.006*	0.001*
Platelets ( $\times 10^9/L$ )	Range	217–402	115–458	251–629
	Median	253.5	232.5	378
	P		0.413	0.001*
MPV	Range	8.6–10.9	7.9–10.7	8.1–10.3
	Median	9.15	9.25	9.2
	P		0.731	0.820
Ferritin (ng/ml)	Range	41–90	804–11400	1070–8700
	Median	58.5	1356.5	3200
	P		0.000*	0.000*

Significance was considered at level of  $P \leq 0.05$ .

\* Significantly different from control group.

\* Significantly different from unsplenectomized group.

With respect to substance P, higher levels were observed in thalassemic patients versus the controls ( $P = 0.000$ ) especially in the splenectomized group ( $P = 0.009$ ) but no significant difference was found between both patient groups. Regarding sP-selectin, it was significantly higher in the patient groups compared to the control ( $P = 0.037$ ) and especially in the splenectomized group compared to unsplenectomized group and the controls ( $P = 0.016$  and  $P = 0.003$  respectively) (Table 2).

A significant positive correlation was found between sP-selectin and plasma substance P ( $P = 0.000$ ), WBCs count ( $P = 0.025$ ), normoblasts ( $P = 0.040$ ) and MCV ( $P = 0.022$ ). Additionally, a borderline significance was found with serum ferritin ( $P = 0.053$ ) while there was no significant correlation with platelet count ( $P = 0.584$ ) or MPV ( $P = 0.867$ ) (Table 3).

With respect to substance P, a significant negative correlation was observed between plasma substance P and MPV ( $P = 0.034$ ). On the other hand, there was no significant correlation between plasma substance P and WBC count ( $P = 0.073$ ), normoblasts ( $P = 0.503$ ), MCV ( $P = 0.083$ ), platelet count ( $P = 0.123$ ) or serum ferritin ( $P = 0.257$ ) in all patients with  $\beta$ -thalassemia major (Table 3).

#### 4. Discussion

A profound hemostatic derangement has been observed in patients with thalassemia<sup>4</sup>, yet the mechanism underlying

this hypercoagulable state is multifactorial.<sup>12–18</sup> Platelet activation has been incriminated. It is caused by the scavenging of endothelial-derived nitric oxide (NO) which causes vasoconstriction and decreased blood flow.<sup>19</sup> Thrombocytosis and spontaneous platelet activation and aggregation, especially after splenectomy remains an attractive pathophysiologic issue.<sup>20</sup> This has been observed in the present study where thrombocytosis was significant in splenectomized patients which by itself predisposes them to thrombosis.

In the present study, a significant increase in sP-selectin was observed in thalassemic patients especially in the splenectomized group reflecting a state of endothelial activation and damage which further enhances platelet activation. This is in agreement with Kanawaki et al.<sup>21</sup> and Krishnan et al.<sup>22</sup> In addition, Kato et al.<sup>18</sup> showed increased plasma levels of vascular cell adhesion molecules (sVCAMs), sE-selectin, sP-selectin in sickle cell patients compared to healthy individuals. In addition, Hayashi et al.<sup>23</sup> reported that P-selectin plays a key role in immune system mediated inflammation through promoting the adherence of leukocytes to activated platelets and endothelium, leukocyte migration, cytokine release and secretion of growth factors at the site of injury. Furthermore, many authors highlighted the role of sP-selectin in arterial thrombogenesis by forming large stable platelet leukocyte aggregates.<sup>24,25</sup> Our findings are also supported by Sullivan et al.<sup>26</sup> and Smyth et al.<sup>27</sup> who demonstrated that venous thrombosis was decreased in P-selectin deficient mice.

**Table 2** Plasma substance P and sP-selectin in all studied groups.

	Control group (n = 10)	Patients with $\beta$ thalassemia major (n = 30)	Patients with $\beta$ thalassemia major		
			Unsplenectomized group (n = 15)	Splenectomized group (n = 15)	
Substance P (pg/mL)	Range	28 – 192	40–7000	40–1820	144– 7000
	Median	125	176	172	182
	P		0.000*	0.061 0.241	0.009*
sP-selectin (ng/mL)	Range	20–42	20–280	20–110	20–280
	Median	30	40	32	50
	P		0.037*	0.472 0.016*	0.003*

Significance was considered at level of  $P \leq 0.05$ .

\* Significantly different from the control group.

\* Significantly different from the unsplenectomized group.

**Table 3** Correlation between plasma substance P and sP-selectin with laboratory parameters in all patients with  $\beta$  thalassemia major.

	Substance P (n = 30)	sP-selectin (n = 30)
WBCs count	$r = 0.317$ $P = 0.073$	$r = 0.391$ $P = 0.025^*$
Normoblasts	$r = 0.121$ $P = 0.503$	$r = 0.359$ $P = 0.040^*$
MCV	$r = 0.307$ $P = 0.083$	$r = 0.398$ $P = 0.022^*$
Platelet count	$r = 0.274$ $P = 0.123$	$r = 0.099$ $P = 0.584$
MPV	$r = -0.369$ $P = 0.034^*$	$r = 0.030$ $P = 0.867$
Serum ferritin	$r = 0.203$ $P = 0.257$	$r = 0.340$ $P = 0.053$
Substance P	–	$r = 0.607$ $P = 0.000^*$

$r$ : Pearson coefficient.

\* Significance was considered at level of  $P \leq 0.05$ .

In the present study, a positive correlation was found between sP-selectin, a marker of platelet activation, and normoblast count reflecting the relation between platelet activation and the subsequent prothrombotic state and normoblasts. This agrees with Garozzo and his colleagues<sup>17</sup> who explained the hypercoagulable status of thalassemic patients by the fact that their normoblasts carried intercellular adhesion molecule-2 (ICAM-2) and platelet endothelial cell adhesion molecule-1 (PECAM-1).

Moreover, the role of red cell size in the pathogenesis of hypercoagulability has been studied by Atichartakarn and his colleagues.<sup>28</sup> They reported that smaller sized RBCs are more thrombogenic especially after splenectomy. Their data suggested that the efficient clearing of these abnormal RBCs by the spleen protects against the hypercoagulable condition.

In the present study a significant increase in the platelet count was observed among splenectomized patients. This is due to the fact that the spleen is the main organ for platelet

sequestration.<sup>10</sup> Moreover, post-splenectomy thrombocytosis, by itself predisposes these patients to thrombosis. Ataga et al.<sup>16</sup> added that splenectomized thalassemic patients had a shortened platelet life span compared to healthy individuals splenectomized for trauma. Eldor and Rachmilewitz suggested that the shortened life span was caused by enhanced platelet consumption, a feature usually associated with active thrombotic disease and hypercoagulable states.<sup>29</sup>

Furthermore, a significant positive correlation was found between plasma sP-selectin and serum ferritin as well as total leucocytic count reflecting the interplay between platelet activation, iron free radicals and inflammation. Our findings are supported by Warefeld and Myers<sup>30</sup> who reported that thrombosis and inflammation are inter-related.

Regarding substance P, to our knowledge it has not been studied in patients with thalassemia. In the present study, significantly elevated levels of substance P were observed in patients with thalassemia compared to the control and the elevated levels were more prominent in splenectomized patients reflecting a higher level of platelet activation.

In the present study, we found a significant positive correlation between substance P and sP-selectin, reflecting the role of substance P in inducing inflammation and platelet activation. In agreement to our findings, Jone et al.<sup>31</sup> defined the role for substance P in the activation of platelet function and thrombus formation. They showed that substance P can stimulate platelet activation and aggregation, and that platelets contain substance P immunoreactivity that is released upon activation. In addition, inhibition or deficiency of the neurokinin receptor 1 (NK1) of this neuropeptide resulted in substantially reduced thrombus formation in vitro. Moreover, Graham et al.<sup>32</sup> stated that NK1 receptor blocking antibodies inhibit platelet responses to collagen, indicating that NK1 agonists are released from activated platelets and act as paracrine agonists.

To the best of our knowledge, this is the first report on tachykinin neuropeptide, substance P in patients with thalassemia. The observed high levels add a new mechanism to the already well established causes of platelet activation and hypercoagulability in thalassemic patients.

## 5. Conclusion

- Substance P and sP-selectin might have a role in platelet activation and subsequent hypercoagulability in thalassaemic patients.
- If proved by large scale studies, P-selectin and substance P could be novel targets in preventing the complications of thalassaemia.

## References

1. Rund D, Rachmilewitz E. Medical progress-Beta-thalassemia. Review article. *N Engl J Med* 2005;**353**:1135–46.
2. Elbeshlawy A, Yossry I. Prevention of hemoglobinopathies in Egypt. *Hemoglobin* 2009;**33**:4–20.
3. Muncie Jr HL, Campbell J. Alpha and beta thalassemia. *Am Fam Physician* 2009;**80**:339–44.
4. Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in  $\beta$ -thalassemia: a status quo. *Expert Rev Hematol* 2012;**5**:505–12.
5. Ley K. The role of selectins in inflammation and disease. *Trends Mol Med* 2003;**9**:263–8.
6. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. *Thromb Haemost* 2001;**86**:746–56.
7. Frenette PS. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. *J Exp Med* 2000;**19**:1413–22.
8. Page NM, Bell NJ, Gardines SM. Characterization of the endokinins: human tachykinins with cardio-vascular activity. *Proc Natl Acad Sci USA* 2003;**100**:6245–50.
9. Willem J, Akkerman N. Neurotransmitters act as platelet activators. *Blood* 2008;**111**:476.
10. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. *Ann NY Acad Sci* 2005;**1054**:317–24.
11. Bain BJ, Lewis SM, Bates I, editors. *Basic haematological techniques*. In: *Dacie and Lewis Practical Haematology*. 10th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2006, pp. 25–57.
12. Haghpahan S, Karimi M. Cerebral thrombosis in patients with  $\beta$ -thalassemia: a systematic review. *Blood Coagul Fibrinolysis* 2012;**23**:212–7.
13. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhouli K, Daar S, et al. Splenectomy and thrombosis: the case of thalassaemia intermedia. *J Thromb Haemost* 2010;**8**:2152–8.
14. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee A, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/ $\beta$ -thalassemia: A consequence of splenectomy. *Int J Hematol* 2003;**77**:299–303.
15. Cappellini MD, Musallam KM, Poggiali E, Taher AT. Hypercoagulability in non-transfusion-dependent thalassaemia. *Blood Rev* 2012;**26**, S20-3.
16. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. *Br J Haematol* 2007;**139**:3–13.
17. Garozzo G, Distefano R, Miceli A, Bonomo P. Detection of ICAM-1, ICAM-2, ICAM-3, PECAM-1 and VCAM-1, evaluation of hypercoagulable state and platelet aggregation in hemoglobinopathy patients with erythroblasts. *Haematologica* 2001;**86**:778–9.
18. Kato GJ, Mastyr S, Blackwelder WC, Nichols Js. Levels of soluble endothelium-derived adhesion molecule in patients with sickle cell disease are associated with pulmonary hypertension and after sickle cell crises. *J Thromb Thrombolysis* 2005;**19**:83–6.
19. Wagner DD, Frenette PS. The vessel wall and its interactions. *Blood* 2008;**111**:5271–81.
20. Jackson SP. The growing complexity of platelet aggregation. *Blood* 2007;**109**:5087–95.
21. Kanawaki I, Makrythansis P, Lazars poulou C, Kattamis A. Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell beta thalassaemia. *Eur J clin Invest* 2012;**42**:27–33.
22. Krishnan S, Setty Y, Betal SG, Vljender V, Rao K, Dampier C, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasoocclusive crises. *B J Haematol* 2010;**148**:797–804.
23. Hayashi SI, Watanabe N, Nakazawa K, Suzuki J. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. *Circulation* 2000;**102**:1710–7.
24. Yokoyama S, Tkeda H, Haramaki N, Yasukawa H. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. *Am Coll Cardiol* 2005;**45**:1280–6.
25. Woollard KJ, Kling D, Kulkarni S, Dart AM. Raised plasma soluble P-selectin in peripheral blood arterial occlusive disease enhances leukocyte adhesion. *Circ Res* 2006;**98**:149–56.
26. Sullivan VV. Decrease in fibrin content of venous thrombi in selectin-deficient mice. *J Surg Res* 2003;**109**:1–7.
27. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Collier BS. B3-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. *Circulation* 2001;**103**:2501–7.
28. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/ $\beta$ -thalassaemic patients. *Br J Haematol* 2002;**118**:893–8.
29. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassaemia. *Blood* 2002;**99**:36–43.
30. Warefield TW, Myers DD. Venous thromboembolism: the intersection of thrombosis and inflammation. *US Hematology* 2007;**52**–4.
31. Jones S, Tucker KL, Sage T, Kaiser WY. Peripheral tachykinins and the neurokinin receptor NK 1 are required for platelet thrombus formation. *Blood* 2008;**111**:605–12.
32. Graham GJ, Stevens JM, Page NM, Grant AD, Brain SD, Lowry PJ, et al. Tachykinins regulate the function of platelets. *Blood* 2004;**104**:1058–65.